Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Edoxaban, sold under the brand name Lixiana among others, is an anticoagulant medication and a direct factor Xa inhibitor. It is taken by mouth.
The analysis highlights Applications, Contraindications and notes and Pharmacokinetics as prominent areas in the source structure around Edoxaban.
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
The extracted context around Edoxaban shows recurring relationship patterns in the source. For example, Edoxaban → CES1, CYP3A4, CYP3A5, Glucuronidation, In, Metabolism, With Another extracted example is Edoxaban → In, Ki, Prothrombinases, Thrombins, Va, Xa. Use these groups to spot repeated connection types before inspecting the individual relationships.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
approved blood anticoagulant anticoagulants embolism bleeding factor also use warfarin urine overdose mouth administration ces1 cyp3a4 hydrolysis risk people may
TTTA extracted 65 structured relationships around Edoxaban. Examples in this analysis include Edoxaban → 3D model (JSmol) → Interactive image and Edoxaban → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Edoxaban | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Edoxaban | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Edoxaban | ATC code | B01AF03 (WHO) | 1.00 | infobox |
| Edoxaban | Bioavailability | 62%; Tmax 1–2 hours | 1.00 | infobox |
| Edoxaban | CAS Number | 480449-70-5 N | 1.00 | infobox |
| Edoxaban | ChEBI | CHEBI:85973 N | 1.00 | infobox |
| Edoxaban | ChemSpider | 8456212 N | 1.00 | infobox |
| Edoxaban | CompTox Dashboard (EPA) | DTXSID50197398 | 1.00 | infobox |
| Edoxaban | DrugBank | DB09075 N | 1.00 | infobox |
| Edoxaban | Elimination half-life | 10–14 hours | 1.00 | infobox |
| Edoxaban | Excretion | 62% feces, 35% urine | 1.00 | infobox |
| Edoxaban | Formula | C24H30ClN7O4S | 1.00 | infobox |
| Edoxaban | IUPHAR/BPS | 7575 | 1.00 | infobox |
| Edoxaban | KEGG | D09710 N | 1.00 | infobox |
| Edoxaban | Legal status | CA: ℞-only | 1.00 | infobox |
| Edoxaban | Legal status | US: ℞-only | 1.00 | infobox |
| Edoxaban | Legal status | EU: Rx-only | 1.00 | infobox |
| Edoxaban | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Edoxaban | License data | US DailyMed: Edoxaban | 1.00 | infobox |
| Edoxaban | MedlinePlus | a614055 | 1.00 | infobox |
| Edoxaban | Metabolism | minimal CES1, CYP3A4/5, hydrolysis, glucuronidation | 1.00 | infobox |
| Edoxaban | Molar mass | 548.06 g·mol−1 | 1.00 | infobox |
| Edoxaban | Other names | DU-176b | 1.00 | infobox |
| Edoxaban | Protein binding | 55% | 1.00 | infobox |
| Edoxaban | PubChem CID | 10280735 | 1.00 | infobox |
| Edoxaban | Routes of administration | By mouth | 1.00 | infobox |
| Edoxaban | Trade names | Savaysa, Lixiana, Roteas, others | 1.00 | infobox |
| Edoxaban | UNII | NDU3J18APO | 1.00 | infobox |
The concept neighborhoods around Edoxaban bring nearby vocabulary together. In this analysis, examples include Anticoagulants, Overdose and Bleeding. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
For Edoxaban, one of the stronger structural bridges in this analysis connects Edoxaban with Contraindications and notes. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
TTTA analyzes the structure around Edoxaban to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Applications, Contraindications and notes & Pharmacokinetics, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
Source: Wikipedia — Edoxaban · EN edition · Analysis: TopicsToTalkAbout